| __timestamp | BioMarin Pharmaceutical Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 461543000 | 505679000 |
| Thursday, January 1, 2015 | 634806000 | 487656000 |
| Friday, January 1, 2016 | 661905000 | 660876000 |
| Sunday, January 1, 2017 | 610753000 | 874278000 |
| Monday, January 1, 2018 | 696328000 | 1431159000 |
| Tuesday, January 1, 2019 | 715007000 | 2386000000 |
| Wednesday, January 1, 2020 | 628116000 | 3137000000 |
| Friday, January 1, 2021 | 628793000 | 4181000000 |
| Saturday, January 1, 2022 | 649606000 | 5562000000 |
| Sunday, January 1, 2023 | 746773000 | 7630000000 |
Unleashing the power of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Genmab A/S and BioMarin Pharmaceutical Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Genmab A/S has shown a remarkable increase in R&D spending, growing by over 1,400%, reaching a peak in 2023. This surge underscores Genmab's aggressive pursuit of groundbreaking therapies. In contrast, BioMarin's R&D expenses have grown more modestly, with a 62% increase over the same period. This steady growth reflects a more conservative approach, focusing on refining existing treatments. The data highlights how these two industry leaders prioritize their resources, offering insights into their strategic visions for the future of healthcare innovation.
Research and Development Expenses Breakdown: Amgen Inc. vs Genmab A/S
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Research and Development: Comparing Key Metrics for Genmab A/S and Summit Therapeutics Inc.
Analyzing R&D Budgets: Genmab A/S vs Celldex Therapeutics, Inc.
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. vs ADMA Biologics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amneal Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.
Comparing Innovation Spending: BioMarin Pharmaceutical Inc. and Soleno Therapeutics, Inc.
Research and Development Investment: BioMarin Pharmaceutical Inc. vs Dynavax Technologies Corporation
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Galapagos NV